AKBA Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 4.10%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $589,215.90

Akebia Therapeutics Insider Trading History Chart

Akebia Therapeutics Share Price & Price History

^$1.92

▲ +0.01 (0.52%)

As of 03/31/2025 05:00 PM ET

Days: 30 | 90 | 365

Akebia Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/3/2025	John P. Butler	CEO	Sell	144,250	$2.10	$302,925.00	2,604,330
2/3/2025	Nicholas Grund	Insider	Sell	55,621	$2.10	$116,804.10	442,579
2/3/2025	Richard C Malabre	CAO	Sell	30,202	$2.10	$63,424.20	280,248
2/3/2025	Steven Keith Burke	SVP	Sell	50,506	$2.10	$106,062.60	816,234
2/29/2024	John P. Butler	CEO	Sell	46,570	$1.58	$73,580.60	2,044,580
2/29/2024	Michel Dahan	COO	Sell	8,661	$1.58	$13,684.38	706,932
2/29/2024	Nicole R Hadas	SVP	Sell	5,974	$1.58	$9,438.92	663,259
2/27/2024	John P. Butler	CEO	Sell	37,733	$1.52	$57,354.16	2,091,150
2/27/2024	Michel Dahan	COO	Sell	10,744	$1.52	$16,330.88	715,593
2/27/2024	Nicole R Hadas	SVP	Sell	7,411	$1.52	$11,264.72	669,233
2/1/2024	John P. Butler	CEO	Sell	46,489	$1.68	$78,101.52	2,128,883
2/1/2024	Steven Keith Burke	SVP	Sell	24,311	$1.68	$40,842.48	711,376
5/25/2023	Michel Dahan	COO	Sell	95,478	$1.22	$116,483.16	574,037
5/25/2023	Nicole R Hadas	SVP	Sell	63,186	$1.22	$77,086.92	524,344
5/16/2023	Steven Keith Burke	SVP	Sell	63,567	$1.07	$68,016.69	530,487
3/1/2023	David A. Spellman	CFO	Sell	7,210	$0.88	$6,344.80	510,050
3/1/2023	John P. Butler	CEO	Sell	91,868	$0.88	$80,843.84	1,568,872
3/1/2023	Michel Dahan	COO	Sell	20,412	$0.88	$17,962.56	269,515
3/1/2023	Nicole R Hadas	SVP	Sell	13,034	$0.88	$11,469.92	287,530
6/3/2022	Steven C Gilman	Director	Sell	4,567	$0.36	$1,644.12	43,430

See Full Table

SEC Filings (Institutional Ownership Changes) for Akebia Therapeutics (NASDAQ:AKBA)

33.92% of Akebia Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Akebia Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
3/24/2025	Wellington Management Group LLP	502,127	$0.95M	0.0%	+24.1%	0.213%
2/20/2025	Mackenzie Financial Corp	135,392	$0.26M	0.0%	+930.4%	0.062%
2/17/2025	Two Sigma Advisers LP	143,149	$0.27M	0.0%	-23.8%	0.066%
2/17/2025	Rafferty Asset Management LLC	179,752	$0.34M	0.0%	N/A	0.082%
2/17/2025	ProShare Advisors LLC	58,585	$0.11M	0.0%	+49.0%	0.027%
2/17/2025	Millennium Management LLC	169,647	$0.32M	0.0%	+738.0%	0.078%
2/17/2025	MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.	126,380	$0.24M	0.0%	+10.7%	0.058%
2/17/2025	Jacobs Levy Equity Management Inc.	1,228,710	$2.34M	0.0%	-39.6%	0.563%
2/17/2025	Deutsche Bank AG	181,048	$0.34M	0.0%	+64.0%	0.083%
2/17/2025	Balyasny Asset Management L.P.	274,452	$0.52M	0.0%	N/A	0.126%
2/17/2025	Bank of America Corp DE	543,916	$1.03M	0.0%	+117.9%	0.249%
2/17/2025	BNP Paribas Financial Markets	34,599	$66K	0.0%	-25.2%	0.016%
2/14/2025	Jane Street Group LLC	202,275	$0.38M	0.0%	+63.5%	0.093%
2/14/2025	Northern Trust Corp	1,685,641	$3.20M	0.0%	+3.1%	0.773%
2/14/2025	Aquatic Capital Management LLC	24,998	$47K	0.0%	N/A	0.011%
2/14/2025	Two Sigma Securities LLC	40,826	$78K	0.0%	+206.8%	0.019%
2/14/2025	Voya Investment Management LLC	63,842	$0.12M	0.0%	-9.3%	0.029%
2/14/2025	Price T Rowe Associates Inc. MD	137,905	$0.26M	0.0%	+8.9%	0.063%
2/14/2025	Hsbc Holdings PLC	70,005	$0.13M	0.0%	+27.3%	0.032%
2/14/2025	TD Waterhouse Canada Inc.	98,618	$0.19M	0.0%	+8.8%	0.045%
2/14/2025	MetLife Investment Management LLC	104,030	$0.20M	0.0%	+52.8%	0.048%
2/14/2025	Dimensional Fund Advisors LP	125,680	$0.24M	0.0%	N/A	0.058%
2/13/2025	Mariner LLC	14,944	$28K	0.0%	N/A	0.007%
2/13/2025	Barclays PLC	375,495	$0.71M	0.0%	+37.5%	0.172%
2/13/2025	Raymond James Financial Inc.	44,748	$85K	0.0%	N/A	0.021%
2/13/2025	Renaissance Technologies LLC	3,823,527	$7.27M	0.0%	+2.8%	1.752%
2/13/2025	Federated Hermes Inc.	914,003	$1.74M	0.0%	+5.3%	0.419%
2/13/2025	Russell Investments Group Ltd.	110,930	$0.21M	0.0%	-34.9%	0.051%
2/13/2025	Wells Fargo & Company MN	122,397	$0.23M	0.0%	+23.3%	0.056%
2/12/2025	Geode Capital Management LLC	4,795,095	$9.11M	0.0%	+0.9%	2.198%
2/12/2025	Diametric Capital LP	88,115	$0.17M	0.1%	N/A	0.040%
2/12/2025	Wellington Management Group LLP	502,127	$0.95M	0.0%	+24.1%	0.230%
2/12/2025	JPMorgan Chase & Co.	456,294	$0.87M	0.0%	+363.0%	0.209%
2/11/2025	Corebridge Financial Inc.	103,422	$0.20M	0.0%	-7.0%	0.047%
2/11/2025	Vanguard Group Inc.	10,884,200	$20.68M	0.0%	+8.1%	4.989%
2/11/2025	Intech Investment Management LLC	118,209	$0.23M	0.0%	+162.3%	0.054%
2/10/2025	PDS Planning Inc	15,000	$28K	0.0%	N/A	0.007%
2/10/2025	Cibc World Markets Corp	19,468	$37K	0.0%	N/A	0.009%
2/10/2025	Connor Clark & Lunn Investment Management Ltd.	1,026,896	$1.95M	0.0%	-1.9%	0.471%
2/6/2025	Raymond James Financial Inc.	44,748	$85K	0.0%	N/A	0.021%
2/6/2025	Charles Schwab Investment Management Inc.	586,710	$1.12M	0.0%	+3.2%	0.269%
2/5/2025	SRS Capital Advisors Inc.	13,700	$26K	0.0%	N/A	0.006%
2/4/2025	Bank of New York Mellon Corp	497,547	$0.95M	0.0%	+5.9%	0.228%
1/30/2025	Rhumbline Advisers	265,389	$0.50M	0.0%	+9.3%	0.122%
1/22/2025	Wealth Effects LLC	32,000	$61K	0.0%	+18.5%	0.015%
1/21/2025	AlphaMark Advisors LLC	38,461	$73K	0.0%	N/A	0.018%
1/17/2025	SG Americas Securities LLC	116,771	$0.22M	0.0%	+62.3%	0.054%
1/15/2025	Empirical Asset Management LLC	13,300	$25K	0.0%	-60.5%	0.006%
12/26/2024	JPMorgan Chase & Co.	98,546	$0.13M	0.0%	+10.9%	0.045%
11/27/2024	Franklin Resources Inc.	167,184	$0.22M	0.0%	N/A	0.077%
11/20/2024	Virtu Financial LLC	55,746	$74K	0.0%	-25.8%	0.026%
11/19/2024	Barclays PLC	273,085	$0.36M	0.0%	+276.1%	0.125%
11/16/2024	Geode Capital Management LLC	4,754,464	$6.28M	0.0%	+4.8%	2.179%
11/15/2024	Barclays PLC	273,085	$0.36M	0.0%	+276.1%	0.125%
11/15/2024	XTX Topco Ltd	44,267	$58K	0.0%	N/A	0.020%
11/15/2024	Jane Street Group LLC	123,728	$0.16M	0.0%	-14.0%	0.057%
11/15/2024	Wellington Management Group LLP	404,718	$0.53M	0.0%	N/A	0.185%
11/15/2024	State Street Corp	3,430,527	$4.53M	0.0%	+24.9%	1.572%
11/15/2024	Jacobs Levy Equity Management Inc.	2,034,169	$2.69M	0.0%	-2.9%	0.932%
11/14/2024	MetLife Investment Management LLC	68,064	$90K	0.0%	+25.7%	0.031%
11/13/2024	BNP Paribas Financial Markets	46,270	$61K	0.0%	+205.8%	0.021%
11/13/2024	FMR LLC	682,038	$0.90M	0.0%	+26.0%	0.313%
11/13/2024	The Manufacturers Life Insurance Company	78,444	$0.10M	0.0%	N/A	0.036%
11/9/2024	Intech Investment Management LLC	45,066	$59K	0.0%	N/A	0.021%
11/1/2024	CWA Asset Management Group LLC	49,000	$65K	0.0%	N/A	0.023%
10/11/2024	Empirical Asset Management LLC	33,700	$44K	0.0%	N/A	0.016%
10/3/2024	SG Americas Securities LLC	71,965	$95K	0.0%	+117.1%	0.034%
8/19/2024	B. Riley Wealth Advisors Inc.	43,360	$44K	0.0%	N/A	0.021%
8/15/2024	Alerce Investment Management L.P.	5,747,906	$5.86M	11.5%	-56.5%	2.742%
8/14/2024	Marshall Wace LLP	247,069	$0.25M	0.0%	-75.9%	0.118%
8/13/2024	Orchard Capital Management LLC	86,826	$89K	0.0%	-19.9%	0.041%
8/12/2024	Marathon Trading Investment Management LLC	52,651	$54K	0.0%	-79.7%	0.025%
8/12/2024	Mercer Global Advisors Inc. ADV	31,221	$32K	0.0%	+40.7%	0.015%
8/9/2024	Renaissance Technologies LLC	3,914,800	$3.99M	0.0%	+7.2%	1.868%
8/6/2024	Acadian Asset Management LLC	4,063,383	$4.14M	0.0%	-23.5%	1.939%
8/1/2024	Rhumbline Advisers	247,060	$0.25M	0.0%	+4,915.4%	0.118%
7/26/2024	Bank of New York Mellon Corp	604,551	$0.62M	0.0%	+3,122.2%	0.288%
7/18/2024	Assenagon Asset Management S.A.	211,647	$0.22M	0.0%	-73.2%	0.101%
7/12/2024	SG Americas Securities LLC	33,144	$34K	0.0%	N/A	0.016%
5/16/2024	Jacobs Levy Equity Management Inc.	1,637,578	$3M	0.0%	-11.8%	0.781%
5/15/2024	Lazard Asset Management LLC	43,545	$79K	0.0%	N/A	0.021%
5/10/2024	Acadian Asset Management LLC	5,309,755	$9.72M	0.0%	-23.2%	2.536%
5/10/2024	Vanguard Group Inc.	8,225,972	$15.05M	0.0%	+8.1%	3.929%
4/24/2024	Assenagon Asset Management S.A.	790,483	$1.45M	0.0%	N/A	0.378%
4/18/2024	Compass Ion Advisors LLC	25,095	$46K	0.0%	N/A	0.012%
4/17/2024	Cannon Global Investment Management LLC	28,000	$51K	0.1%	N/A	0.013%
2/15/2024	Orchard Capital Management LLC	86,826	$0.11M	0.0%	+29.9%	0.044%
2/6/2024	Sapient Capital LLC	200,000	$0.25M	0.0%	N/A	0.101%
2/5/2024	Victory Capital Management Inc.	22,519	$28K	0.0%	-97.0%	0.011%
2/5/2024	Eagle Wealth Strategies LLC	20,017	$25K	0.0%	N/A	0.010%
1/31/2024	Federated Hermes Inc.	866,554	$1.08M	0.0%	-10.2%	0.460%
1/31/2024	Archer Investment Corp	19,800	$25K	0.0%	N/A	0.011%
1/30/2024	Mackenzie Financial Corp	23,159	$29K	0.0%	+37.6%	0.012%
1/29/2024	Sapient Capital LLC	200,000	$0.25M	0.0%	N/A	0.106%
1/16/2024	Raymond James & Associates	29,917	$37K	0.0%	+48.0%	0.016%
12/6/2023	Citigroup Inc.	152,737	$0.17M	0.0%	+311,608.2%	0.081%
11/13/2023	Acadian Asset Management LLC	7,223,488	$8.23M	0.0%	-3.2%	3.834%
11/6/2023	Victory Capital Management Inc.	755,488	$0.86M	0.0%	+14.1%	0.401%
8/7/2023	Acadian Asset Management LLC	7,460,353	$6.82M	0.0%	-0.3%	4.012%
8/3/2023	Mackenzie Financial Corp	27,199	$25K	0.0%	-34.3%	0.015%

Data available starting January 2016

See Full Table

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $1.92

$1.83

$1.94

50 Day Range

MA: $2.08

$1.69

$2.84

52 Week Range

Now: $1.92

$0.80

$2.89

Volume

3,604,426 shs

Average Volume

2,821,089 shs

Market Capitalization

$453.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.94

Who are the company insiders with the largest holdings of Akebia Therapeutics?: Akebia Therapeutics' top insider shareholders include:
John P Butler (CEO)
Steven Keith Burke (SVP)
Michel Dahan (COO)
Nicole R Hadas (SVP)
Nicholas Grund (Insider)
Richard C Malabre (CAO)
Learn More about top insider investors at Akebia Therapeutics.
Who are the major institutional investors of Akebia Therapeutics?: Akebia Therapeutics' top institutional investors include:
Vanguard Group Inc. — 4.99%
Geode Capital Management LLC — 2.20%
Renaissance Technologies LLC — 1.75%
Northern Trust Corp — 0.77%
Jacobs Levy Equity Management Inc. — 0.56%
Connor Clark & Lunn Investment Management Ltd. — 0.47%
Learn More about top institutional investors of Akebia Therapeutics stock.
Which institutional investors are selling Akebia Therapeutics stock?: Within the last quarter, AKBA stock was sold by these institutional investors:
Jacobs Levy Equity Management Inc.
Group One Trading LLC
Russell Investments Group Ltd.
Two Sigma Advisers LP
Empirical Asset Management LLC
Connor Clark & Lunn Investment Management Ltd.
BNP Paribas Financial Markets
Corebridge Financial Inc.
Within the last year, company insiders that have sold Akebia Therapeutics company stock include:
John P Butler (CEO)
Steven Keith Burke (SVP)
Michel Dahan (COO)
Nicole R Hadas (SVP)
Learn More investors selling Akebia Therapeutics stock.
Which institutional investors are buying Akebia Therapeutics stock?: Within the previous quarter, AKBA stock was acquired by institutional investors including:
Vanguard Group Inc.
JPMorgan Chase & Co.
Bank of America Corp DE
Balyasny Asset Management L.P.
Rafferty Asset Management LLC
Millennium Management LLC
Dimensional Fund Advisors LP
Mackenzie Financial Corp